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 The goal of these studies was to characterize hit compounds identified in a high-
content screen of over 220,000 compounds in a glucocorticoid receptor (GR) translocation assay.  
Hit compounds were those compounds that reproducibly inhibited the dexamethasone-induced 
translocation of GR from the cytoplasm to the nucleus in a concentration dependent manner. The 
translocation of GR occurs after glucocorticosteroid binds the ligand binding domain of  GR 
maintained in a high affinity binding state by ATP bound hsp90 in a  hetero-complex that 
includes hsp70, hsp40, Hop, and p23..  After glucocorticosteroid is bound to GR, the GR 
attaches to cytoplasmic dynein and is transported from the cytoplasm to the nucleus. Because the 
translocation of GR from the cytoplasm to the nucleus depends on the activity of both hsp90 and 
cytoplasmic dynein it is possible that a sub-set of hit compounds from the HCS might be hsp90 
or cytoplasmic dynein inhibitors. The focus of this study was shifted to identifying hsp90 
inhibitors after failure to show proof of concept that the previously published cytoplasmic dynein 
inhibitors ciliobrevin A and D could inhibit GR translocation in the GR translocation assay. 
After verification that hsp90 inhibitors do inhibit GR translocation in the GR translocation assay, 
the hit compound list was reduced from approximately 112 compounds down to five compounds 
that were presumed likely to bind hsp90 based on computational analyses.  An ATPase activity 
assay was developed to test these five hit compounds against hsp90 and two other ATPases, 
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myosin and kinesin; both of which are cytoskeletal motor proteins.  Once these enzymes are  
optimized in the ATPase assay, they can be tested with the selected hit compounds.   
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1.0 INTRODUCTION AND BACKGROUND 
1.1. INTRODUCTION 
 
 
According to the American Cancer Society, approximately one of every four deaths in the 
United States is cancer related (1).  It is estimated there will be 1,658,370 new cancer cases in 
2015 in the United States alone, with an estimated 589,430 cancer related deaths (excluding 
basal cell and squamous cell skin cancer and in situ carcinoma except urinary bladder cancer) 
(1).  However because of earlier diagnoses and improved therapies, the five-year relative 
survival rate for all cancers in 2004-2010 was 68% as compared to only 49% in 1975-1977 (1).  
Based on these statistics, there is still a need for new and improved cancer therapies.    
The original purpose of this study was to identify selective small-molecule inhibitors of 
cytoplasmic dynein.  Cytoplasmic dynein is the major minus-end (towards the nucleus) 
microtubule-associated-transport protein (2).  Along with transporting various cargoes, 
cytoplasmic dynein is also involved in several mitotic functions such as nuclear envelope 
breakdown, centrosome positioning, and cytokinesis (3).  A previous study has shown that 
knockdown of cytoplasmic dynein with RNAi delays but does not completely stop mitosis (4).  
Based on the fact that inhibition of cytoplasmic dynein only slows mitosis and does not 
completely stop it (4), an inhibitor of cytoplasmic dynein may be beneficial in the treatment of 
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fast growing tumors and may produce fewer side effects than microtubule perturbagens such as 
paclitaxel.  When this study began there were no known selective small-molecule inhibitors of 
cytoplasmic dynein.  In 2012, the first selective inhibitors of cytoplasmic dynein were identified 
and as of 2015, no new inhibitors have been published, giving rise to the need for novel 
cytoplasmic dynein inhibitors (5).   Utilizing a high-content screen (HCS) focused on inhibition 
of GR-translocation, it was possible to test a chemical library for inhibitors of hsp90 and 
cytoplasmic dynein simultaneously, among multiple other possible targets.   
    
 HCS is a technique used by researchers to measure a given biological activity or 
phenotype in cell populations after treatment with thousands of agents such as small-molecules, 
peptides, and RNAs.  The use HCS was first mentioned in a 1997 publication by Guliono et al in 
which they explored this new technology for the purpose of drug discovery (6).  HCS provides 
researchers with the ability to measure multiple properties or features of the cells concurrently by 
measuring fluorescent signals simultaneously in multiple channels.  This is in contrast to high-
throughput screening providing only a single readout of activity (7) In 1999  Dr. Gordon Hager 
and his group at the National Cancer Institute developed a mouse adenocarcinoma cell line 
(3617.4 cell line) that stably overexpress a rat glucocorticoid receptor attached to a green 
fluorescent protein (GR-GFP) in order to visualize the translocation of the glucocorticoid 
receptor (GR)  from the cytoplasm to the nucleus (8).  Using an HCS assay developed in this 
cell-line, researchers can simultaneously visualize the GR-GFP and the nucleus using Hoechst to 
stain nuclear DNAs, and can measure GR-agonist induced translocation of GR from the 
cytoplasm into the nuclear compartment of the cell (9).  A HCS campaign to identify inhibitors 
of dexamethasone-induced GR-GFP nuclear translocation in 220,000 compounds from the NIH 
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molecular library screening center network (MLSCN) compound library  was conducted by the 
University of Pittsburgh Molecular Library Screening Center (PMLSC, http://pmlsc.pitt.edu/)   in 
the University of Pittsburgh Drug Discovery Institute (9).    3617.4 cells were seeded into assay 
plates and  incubated for 48 hrs in Tet-free media to induce GR-GFP expression and were then 
pre-exposed to 20 μM of  the compound library for 1 hr prior to a 30 min  treatment with 1 μM 
dexamethasone to induce GR-GFP translocation into the nucleus.  Any compound that inhibited 
one or more component of GR translocation would inhibit the translocation.  Positive and 
negative controls included cells that were there treated and not treated with dexamethasone 
respectively.  17-AAG, an hsp90 inhibitor that has previously been shown to block the agonist-
induced nuclear translocation of steroid nuclear receptors including GR, was used to validate the 
GR-GFP translocation assay during development of the HCS assay (9,10).  Two fluorescent 
channels were independently acquired by the automated fluorescence imager; GR-GFP in the 
FITC channel and Hoechst stained nuclei in the DAPI channel .  Nuclear and cytoplasmic 
regions were trained into a molecular image analysis algorithm by user-defined thresholds; 
described in detail in the ‘METHODS” section of chapter 2.  The molecular image analysis 
algorithm calculated translocation of the GR-GFP by subtracting the mean average GR-GFP 
intensity in the cytoplasmic ring region from the GR-GFP intensity in the nuclear region to 
produce a mean circ-ring intensity difference (9, 10). 
The GR is a ligand-activated transcription factor that belongs to the nuclear receptor 
superfamily, one of the most abundant classes of transcriptional regulators in animals (11).   GR 
regulates a variety of physiological functions such as metabolism, development, differentiation, 
and reproduction (12).   In the absence of glucocorticoid steroid the GR is primarily found in the 
cytoplasm existing as a large complex bound to chaperone proteins hsp90, hsp70, hsp40, hsp 
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organizer protein (Hop), p23 and immunophilins.  GR is in a ligand competent state when bound 
in this heterocomplex (13).  The conformational changes brought about by hsp90-hsp70-hsp40-
Hop in the complex allow the ligand-binding pocket to be open and available to bind 
glucocorticoid steroids (Figure 1). This complex binds the GR, and the binding of ATP by hsp90 
causes a conformational change in the GR to the “open” position in its ligand-binding domain 
(LBD), allowing the GR to bind glucocorticoid steroid (14).  After the GR LBD is in the open 
confirmation and ready to accept glucocorticoidsteroid, Hop and hsp70 leave the heterocomplex 
and p23 binds and stabilizes the heterocomplex.  In the heterocomplex Hop is bound to the 
tetratricopeptide repeat  (TRP) domain of hsp90 and after its release the hsp90 TRP domain 
binds the immunophilin FKBP52.  The GR heterocomplex is then linked to cytoplasmic dynein 
via a protein-protein interaction with FKBP52 (Figure 2). Upon glucocorticoid binding, the GR 
is activated and rapidly transported from the cytoplasm to the nucleus along microtubules by 
cytoplasmic dynein where it binds to DNA and regulates the transcriptional activity, either 
positively or negatively, of its target genes (13, 14). 
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Figure 1: GR Ligand-Binding Domain (cleft) Opening by Hsp70 and Hsp90 
Hydrolysis of ATP by hsp70 bound in the GR hetero-complex primes the complex to be 
ready to bind hsp90.  Once bound to the hetero-complex, hsp90 binds ATP causing a 
conformational change that opens the ligand binding domain, making it ready to bind 
glucocorticoid steroid.  The binding of p23 to hsp90 stabilizes the ATP bound confirmation of 
hsp90. Figure adapted from Pratt et al. (14) 
 
The translocation of  GR occurs after glucocorticoid steroid binding to the LBD of  GR 
maintained in a high affinity binding state by ATP-bound hsp90 in a  hetero-complex that 
includes hsp70, hsp40, Hop, and p23..  After glucocorticoid steroid is bound to  GR, the GR 
attaches to cytoplasmic dynein and is  transported from the cytoplasm to the nucleus.  Inhibition 
of hsp90 has been shown to inhibit translocation of the GR (9,10, 14).  Since GR is one of the 
cargos transported by cytoplasmic dynein, it is also likely that inhibition of cytoplasmic dynein 
would inhibit GR-translocation (10). Because the translocation of GR from the cytoplasm to the 
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nucleus depends on the activity of both hsp90 and cytoplasmic dynein it is possible that a sub-set 
of hit compounds from the HCS might be hsp90 or cytoplasmic dynein inhibitors.  Compounds 
inhibiting GR-translocation could also be inhibiting a number of other proteins such as hsp70, 
hsp40, Hop, p23, immunophilins, and alpha and beta importins.  Another possibility is that a sub-
set of the hit compounds were antagonists of glucocorticoid steroid binding to GR.  
 Hsp90 is a molecular chaperone protein that is important in many cellular processes such 
as cell cycle control and cell survival (15).  This versatile chaperone protein also aids in the 
function and stabilization of many proteins including oncoproteins, which makes hsp90 the 
target of new cancer therapies (15, 16).  Cancers cells have a higher sensitivity to hsp90 
inhibitors than normal cells.  Hsp90 derived from cancer cells have a higher affinity for hsp90 
inhibitors, most likely due to hsp90 in cancer cells being in large multichaperone-client protein 
complexes that differ from the complexes formed in normal cells (17).   For example, hsp90 
derived from cancers cells have 100-fold higher affinity for the hsp90 inhibitor 17-AAG than 
hsp90 derived from normal cells (17).  Recently, several hsp90 inhibitors have failed in clinical 
trials for reasons ranging from poor pharmacokinetic properties to manufacturing difficulties, 
thus creating a need for novel hsp90 inhibitors (3).  
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Figure 2:  The GR-hsp90-immunophilin Complex Attaches to Cytoplasmic Dynein for 
Retrograde Transport Along Microtubules Towards the Nucleus. 
Hsp70 is drawn with a dotted line because once the GR LBD is in the open position Hop and 
hsp70 leave the hetero-complex, however small amounts of hsp70 stay weakly bound.  Once 
Hop and most of hsp70 leave the hetero-complex p23 stabilizes the hsp90 dimer. IC: 
intermediate chain dynein; HC: heavy chain dynein; IMM: immunophilin FKBP52; GR: 
glucocorticoid receptor; hsp90: heat-shock protein 90. Figure adapted from Pratt et al 2004 (14) 
 
In eukaryotes there are three main families of cytoskeletal motor proteins: myosins, 
kinesins, and dyneins (2, 3).  Prokaryotes have different motor proteins.  All of these families of 
protein utilize the hydrolysis of ATP to ADP to power their motor protein domain and thus their 
movement along cytoskeletal polymers.  Myosins travel along actin filaments; kinesins and 
dyneins travel along microtubules (3).   The transport of cargo differs between dynein and 
kinesin in that dynein travels towards the minus-end of microtubules , whereas most kinesins 
(with the exception of the kinesin 14 family) travel towards the plus-end of microtubules (away 
from the nucleus) (2).   
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  Two classes of dyneins, axonemal and cytoplasmic dynein, have been identified.  Of 
these there have been 13 forms identified as axonemal and only two forms identified as 
cytoplasmic dynein (18).   Axonemal dyneins are anchored within the axoneme and aid in the 
coordinated beating of cilia and flagella (19). The two forms of cytoplasmic dynein, cytoplasmic 
dynein 1 and dynein1b (also known as intraflagellar transport dynein), have very different 
distributions and range of function.  Dynein 1b has a specific and restricted cellular distribution, 
primarily expressed in ciliated epithelial cells, and a limited range of function, while dynein 1 
has a wider cellular distribution with multiple functions (18).   Cytoplasmic dynein 1 is involved 
in transport of organelles, mRNAs, and proteins as well as several mitotic functions such as 
nuclear envelope breakdown, centrosome positioning, and cytokinesis (3, 18).  
All dyneins are found in a multi-subunit complex and each form of dynein contains a 
conserved heavy chain (HC) (Molecular weight >500 kDa) (18).  Cytoplasmic dynein HC is 
found as a homodimer linked by the N-terminal tail (19). The motor domain of the HC of dynein 
consists of six ATPase Associated with diverse cellular Activities (AAA+) domains.  The AAA1 
and AAA3 domains carry out most of the ATP hydrolysis (20).  The AAA2 and AAA4 domains 
can also bind ATP, but AAA5 and AAA6 have lost their nucleotide binding sites (19, 20).   
Many subunits of dynein associate with the heavy chain on the N-terminus tail such as light 
chains, light intermediate chains, and intermediate chains of dynein (19).  These proteins, as well 
as other proteins and a complex named dynactin, are vital for the association of cytoplasmic 
dynein to cargo (19, 21).   Dynactin is a multi-protein complex that enhances dynein’s mobility 
along microtubules and serves as an adaptor that allows dynein to bind cargo and these proteins 
are also possible targets of the phenotypic GR-GFP nuclear transport assay (22).  Two major 
protein subunits of dynactin are p150Glued and dynamitin.  Dynein attaches to dynactin through an 
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interaction between the dynein intermediate chain and p150Glued.  P150Glued also binds 
microtubules, which not only stabilizes dynein’s attachment to microtubules, but also increases 
the rate at which dynein moves along microtubules (22).    Dynactin exists in multiple protein 
subunits that are linked together by dynamitin.  Overexpression of recombinant dynamitin 
inhibits dynein transport by destabilizing the endogenous structure of dynactin (21).  Before the 
discovery of the first selective small-molecule inhibitors of cytoplasmic dynein (ciliobrevin A 
and D) in 2012, the only tools available to researchers to inhibit cytoplasmic dynein were 
antibodies specific for dynein light and intermediate chains and overexpression of dynamitin (5) 
Varying protein compositions of the pointed end of dynactin are thought to determine the cargo 
that will associate with the complex and therefore be transported by dynein.  The subunit pairs 
p62/Arp11 and p27/p25 allow dynactin to bind different cellular components during different 
stages of the cell cycle.  This is important to allow dynein to drive the distinctly different types 
of motility required during interphase and at the beginning of mitosis (23).  Yeast lack p62, p27, 
and p25 which suggests that many of dynactin’s functions are independent of these subunits (22, 
23). 
To characterize the hit compounds from the HCS, they were analyzed for promiscuity  
using PubChem (24), a pan assay interference compounds (PAINS) database (25), a medicinal 
chemistry analysis using Instant JChem (24), a docking simulation against hsp90 using SYBYL 
(26), and an ATPase assay to verify selectivity for hsp90.   The PubChem cross target query and 
PAINS database were used to eliminate promiscuous compounds from the hit compound list.  
Instant JChem was used to perform a medicinal chemistry analysis in order to identify 
compounds that had acceptable drug-like properties.  The SYBYL software was used in a 
docking simulation to predict hit compounds that were likely to bind hsp90.  To determine 
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selectivity of the hit compounds, they will be tested in the PiPerTM assay kit (enzyme coupled 
amplex red biochemical assay) against the ATPase activities of hsp90, myosin, and kinesin. 
 Myosin and kinesin are intracellular transport proteins that utilize the energy release 
from ATP hydrolysis to transport cargoes (2).   Although similar in structure and function, 
myosin transports cargoes along actin filaments and kinesin transports cargoes along 
microtubules (2).  Kinesin and myosin have very similar catalytic domain structures when 
observed by x-ray crystallography even though they have very different amino acid sequences 
(28).  Both of these motor proteins move in a hand-over-hand fashion as well (2).    Myosin was 
chosen as a protein to evaluate the selectivity of hit compounds not only because it is an ATPase 
(hsp90 and cytoplasmic dynein are also ATPases), but also because purealin, a novel compound 
isolated from the sea sponge Psammaplysilla purea, inhibits cytoplasmic and axonamal dynein 
and myosin, but does not inhibit other ATPases.  Purealin inhibits dynein and myosin without 
competing for the ATP binding site (29).   Both apomorphine enantiomers, R and S, inhibit both 
cytoplasmic dynein and myosin with similar IC50’s (10).  Based on these findings, an inhibitor of 
cytoplasmic dynein may also inhibit myosin, and it would be important to verify that a 
compound found to inhibit cytoplasmic dynein does not also inhibit myosin.  The fact that 
myosin is an ATPase also makes it a good choice to test the selectivity of compounds inhibiting 
hsp90.  Kinesin is also an ATPase, which makes it a good choice to test against inhibitors of 
hsp90 and cytoplasmic dynein. Kinesin is a microtubule associated protein like cytoplasmic 
dynein and inhibition of either protein may occur by inhibition of microtubule binding, a 
mechanism that can be examined if ATPase inhibition is ruled out as the mechanism of 
inhibition.  Kinesin and dynein are not structurally similar, but they do both bind microtubules 
(4).  Hit compounds that inhibited GR translocation can be characterized as selective inhibitors 
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of hsp90, cytoplasmic dynein, myosin, or kinesin ATPase activity.  A compound that inhibits 
either hsp90 or cytoplasmic dynein’s ATPase activity and not myosin or kinesin’s ATPase 
activity would be considered a selective inhibitor of hsp90 or cytoplasmic dynein. 
 
 
1.2 HSP90 
Hsp90 is a molecular chaperone protein that is ubiquitous and abundant in many cell 
types (15).  It plays an important role in many cellular processes including cell cycle control, cell 
survival, hormone and other signaling pathways (15).  Hsp90 interacts with proteins (clients) and 
is responsible for their maturation and activation (30).  Many hsp90 clients are kinases or 
transcription factors, such as the GR. Recently it has been suggested that up to 10% of all 
proteins require hsp90 to function (31).   
Hsp90 has three main structural domains: an N-terminal ATP binding site, a middle 
domain connected to the N-terminal domain via variable charged linkers, and a C-terminal 
domain responsible for dimerization (32) (Figure 3). The N-terminal domain of hsp90 binds ATP 
quickly, but with low affinity.  The rate-limiting step of hsp90’s ATPase activity is the 
hydrolysis of ATP (33, 34).  ATP binding and hydrolysis are essential for the function of hsp90 
(35).  Although it was originally thought that the linker region between the N-terminal domain 
and the middle domain was just a spacer, recent studies have suggested that this linker region can 
modulate the activity of hsp90 (32, 36). Upon ATP binding the N-terminal domain of hsp90, 
dimerization occurs at the C-terminal domain.  The C-terminal domain can then bind TPR 
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proteins, such as immunophilins, on its MEEVD motif (32) (Figure 3).  Hsp90 is functional as a 
chaperone protein once it binds client proteins and forms a dimer.  Yeast hsp90 (hsc82) was 
chosen as the hsp90 to test ATPase activity in this study due to the fact that it has 10-fold higher 
activity than that of human hsp90 and to take advantage of previously established expression and 
purification techniques available through the Brodsky lab (20).   
 
Figure 3: Structure of Hsp90 
The N-terminal domain of hsp90 contains the ATP binding site. Upon ATP binding  
dimerization occurs at the C-terminal domain. This is linked to the middle domain by a variable 
charged linker region. The Middle domain of hsp90 contains the catalytic loop required for 
ATPase activity.  The C-terminal domain is where dimerization occurs.  At the end of the C-
terminal there is a MEEVD motif where Hop and immunophilins bind.  NTD=N-terminal 
domain; MD = Middle Domain; CTD=C-Terminal Domain Figure adapted from Jackson 2013 
(32)  
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1.3HSP 90 AS A DRUG TARGET 
Hsp90 is a well-known target for anti-tumor and anti-proliferative drugs, and has also 
been shown to sensitize cells to the toxic effects of both chemotherapy and radiotherapy (16).  
Cancer cells have been found to have a higher sensitivity to hsp90 inhibitors, which accumulate 
at higher concentrations in cancer cells as compared to normal cells (17).   Hsp90 inhibitors may 
accumulate in higher concentration in cancer cells because cancer cells express much more 
hsp90 than normal cells.  It could also be due to the fact that the hetero-complexes of hsp90 
expressed in cancer cells have an increased affinity for hsp90 inhibitors (32).  Hsp90 derived 
from tumor cells has been found to have 100-fold higher binding affinity to 17-AAG (hsp90 
inhibitor) than that derived from normal cells (17).  This makes hsp90 an excellent target for 
cancer therapies in that the inhibitors are likely to have more of an effect on cancer cells than 
normal cells.  Several hsp90 inhibitors have progressed to clinical trails, though none have FDA 
approval due to poor drug-like properties, off target toxicity, and manufacturing issues (16). The 
control inhibitor of GR-translocation used to validate the original HCS was 17-AAG, an hsp90 
inhibitor, so it is possible that some of the hit compounds identified in the screen could be novel 
hsp90 inhibitors.   
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2.0 GR-GFP TRANSLOCATION ASSAY 
2.1 INTRODUCTION 
 The original high content phenotypic cell-based screen was carried out with the goal of 
identifying novel inhibitors of Dex-induced GR trafficking, of which cytoplasmic dynein and 
hsp90 inhibitors are a possible subset.  However, as the results in this chapter show, the recently 
identified cytoplasmic dynein inhibitors ciliobrevin A and D were unable to inhibit 
Dexamethasone-induced GR-GFP translocation. Hsp90 inhibitors 17-AAG and STA-9090 and 
microtubule perturbagens vinblastine, vinorelbine, cabazitaxel, ixabepilone, doclitaxel, 
paclitaxel, and vincristine were also tested in the GR-GFP translocation assay as well as a novel 
hsp70 inhibitor, Mal3-101, that was provided by the Brodsky lab, University of Pittsburgh. After 
efforts to purify cytoplasmic dynein failed and based on previous observations that 17-AAG 
inhibited Dex-induced GR-GFP translocation (9, 10)   the focus of this project was shifted to 
focus primarily on identifying novel inhibitors of hsp90.  
 Hit compounds were identified in the HCS by their ability to inhibit dexamethasone-
induced GR translocation into the nucleus.  Compound identities were then confirmed using 
liquid chromatography and mass spectroscopy (LC-MS) to confirm that the expected molecular 
weight species was present and the  percent purity was ≥ 90%.  Activity was confirmed by 
retesting hit compounds in the GR translocation assay.  IC50s were then determined and the hit 
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compound list was reduced by IC50 cut-offs of 10µM and 8µM.  The structures of the hit 
compounds were also analyzed for reactivity and ease of synthesis. 
 
 
2.2 Specific Aim 
 The goal of this aim was to identify which target protein involved in the GR-GFP 
translocation assay would be best to concentrate on to identify a small-molecule inhibitor for 
from the list of 112 hit compounds from the original screen.  In the original screen hit 
compounds were identified from a scaffold diverse library of over 220,000 compounds from the 
NIH’s Molecular Libraries Screening Centers Network library.  The cell-based high content 
screen involved mouse adenocarcinoma cells that express a GR-GFP construct using a tet-
repression system (tetracycline in the media inhibits expression of the construct).  This assay 
allows us to visualize the transport of the GR by cytoplasmic dynein towards the nucleus in the 
presence of compounds and the GR agonist dexamethasone.  
 
2.3 METHODS 
 
Inhibitors of hsp90, hsp70, microtubules, and dynein were tested for their ability to 
inhibit GR translocation using the original high content/information assay using a 3617.4 mouse 
mammary adenocarcinoma cell line that expresses a rat GR-GFP construct controlled by a tet-off 
system (8).  Cells were grown to 70% confluency in Duldecco’s Modified Eagle Medium 
(DMEM) containing 1X nonessential amino acids, 1X sodium pyruvate, 1X penn/strep, 10% 
fetal bovine serum (FBS), 10µg/mL tetracycline, and 0.96mg/mL G418 in an incubator at 37°C, 
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5% CO2, and 95% humidity.  Once at 70% confluency, determined visually under a microscope, 
the cells were washed with DMEM containing all the components from the growth media (listed 
above) with the exception of no tetracycline and charcoal-filtered FBS instead of normal FBS.  
Cells were harvested by trypsinization followed by centrifugation at 500 x g for five minutes and 
re-suspendion in tet-free media.  Viable cells, determined by the exclusion of trypan blue, were 
counted in a hemocytometer.   Cells were seeded at 2,500 cells per well in a 384-well plate and 
incubated for 48 h in DMEM media at 37°C, 5% CO2, and 95% humidity.  After 48 h the cells 
were treated with inhibitors of hsp90, hsp70, microtubules and dynein at a final concentration of 
20µM and incubated at 37°C for 1, 3 or 24 hours.  The cells were then treated with a 
concentration of dexamethasone (100nM) that causes a 100% increase in nuclear GFP 
accumulation (as determined by a dexamethasone titration) and incubated for 30 min at 37°C.  
Following dexamethasone treatment, cells were fixed with 3.7% formaldehyde and stained with 
a Hoechst stain (2µg/mL).  After incubation at room temperature for 30 min, fluorescence 
images were acquired using the ImageXpress Micro automated high content imaging platform 
(Molecular Devices LLC, Menlo, CA) (9). 
The translocation enhanced  image analysis algorithm defined the nucleus of each cell as 
objects that exhibited a fluorescent intensity in the DAPI channel (Hoechst channel) that were 
above background and the appropriate size, defined using the ImageXpress software tools to 
measure nuclear diameters, areas, and intensities over background. .  The nuclear inner mask was 
eroded by 1 pixel to reduce cytoplasmic contamination of the GR-GFP channel (FITC) in the 
nuclear area in order to quantify the amount of GR-GFP signal in the nucleus.  The cytoplasmic 
outer region was defined by dilating the nuclear mask through the cytoplasm as much as possible 
without moving outside of the cellular boundary and then subtracting the original nuclear region.  
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The width of the cytoplasmic outer region was 3 pixels.  This cytoplasmic outer region was then 
used to quantify the amount of GR-GFP signal in the cytoplasm.  The translocation enhanced 
image analysis algorithm quantifies the cell count through the DAPI channel and the average 
fluorescent intensities of the nuclear (Inner) and the cytoplasm (Outer) regions.   To calculate the 
translocation of GR-GFP from the cytoplasm to the nucleus the algorithm calculated a mean 
average intensity ratio by dividing the average GR-GFP intensity of the Inner region by the 
average GR-GFP intensity of the outer region (9, 10). 
Optimal assay conditions for the GR-GFP translocation assay were determined 
experimentally before testing the inhibitors in the assay (9).  For the first optimization step plates 
containing dexamethasone treated cells were either aspirated first and then treated with 
formaldehyde or treated with formaldehyde and then aspirated to determine the order producing 
the optimal results (Figure 5).  The next optimization step was to determine the optimal time to 
treat the cells with dexamethasone.  Cells were treated with dexamethasone and then fixed at 0, 
5, 10, 20, 30, 60, 90, and 120 minutes and then read on the IXU platform (Figure 6).  The final 
optimization step was to determine the optimal concentration of dexamethasone the cells should 
be treated with to insure maximal translocation (Figure 7).  Cells were treated with serial 
dilutions of dexamethasone in the range of 1 x 10-4nM to 1 x 102nM. 
 
2.4 Results 
A. Optimization of GR-GFP Translocation Assay 
 Figure 4 presents representative color composite fluorescent images of 3617.4 cells  
cultured for 48 hours in tet-free media and then treated for 30 min with  100nM dexamethasone 
+ 0.5% DMSO (Figure 4B) or media containing 0.5% DMSO without dexamethasone (Figure 
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4A).  In cells treated with 0.5% DMSO, minus dexamethasone, the GR-GFP appears to be found 
predominately found in the cytoplasm of the 3617.4 cells (Figure 4A).  In contrast, cells treated 
with 100nM dexamethasone for 30 minutes the GR-GFP was almost exclusively localized within 
the nuclear region (Figure 4B). Each optimization step was carried out in triplicate and on three 
separate days, each figure is the best representations of each. Figure 5 compares the results of 
aspirating or fixing first to determine the order giving the most consistent results.  Comparing the 
two orders it is apparent that is it is not important which is done first, aspirate or fix.  The next 
optimization step was to determine how long the cells should be treated with dexamethasone 
before they are fixed with formaldehyde (Figure 6).  Maximumal GR-GFP translocation was 
accomplished at 20 minutes.  Based on those results, 30 minutes was determined to be the 
optimal exposure time for  dexamethasone prior to fixing  cells in formaldehyde to reduce 
variation between experiments.  The final optimization was to determine the optimal 
concentration of dexamethasone to use (Figure 7).  The goal was to find a concentration that was 
well into the maximal translocation range.  Based on the results shown in figure 7, it was 
determined that 100nM dexamethasone should be sufficient to attain maximal GR-GFP 
translocation.   The EC50 was calculated to be approximately 0.92nM, which is consistent with 
previously published results (9)   
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Figure 4:  Color Composite Images of Dexamethasone Treated (B) and Untreated (A) 
3617.4 Cells 
Representative images  presented here are from one  of 3 separate experiments performed 
on  three separate days. 
Color composite images of GR-GFP  (green) and the Hoechst stained nuclei   (blue).  Before 
treatment with dexamethasone the GR-GFP is predominantly located  in the cytoplasm.  After 
dexamethasone treatment (100nM) the GFP is found primarily in the nucleus. 
 
A B 
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Figure 5:  Determine Order of Aspiration and Fixation for Dexamethasone-induced GR-
GFP Nuclear Translocation. 
3617.4 Cells expressing GR-GFP were treated for 30 minute with 100nM dexamethasone (dex) 
or no dex and treated with 3.7% formaldehyde either before (B) or after (A) aspiration of media.  
The error bars represent standard deviation.  Each treatment was completed in triplicate.  The Y-
axis is the inner/outer ratio calculated by dividing the inner (nucleus) intensity by the outer 
(cytoplasm) intensity .  Data representative of three experiments run three separate days.    
A 
B 
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Figure 6:  Time Course of Dexamethasone-induced GR-GFP Nuclear Translocation 
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Cells were treated with 100nM dexamethasone at different incubation times and fixed at the end 
of each time point.  The Y-axis is the Inner/Outer ratio calculated by dividing the inner (nucleus) 
intensity by the outer (cytoplasm) intensity. The X-axis is time in minutes 
Data is representative of three separate experiments run three separate days.  All treatments were 
run in triplicate and error bars are in standard deviation. 
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Figure 7:  GR-GFP Nuclear Translocation Dexamethasone-induced Concentration 
Response 
3617.4 cells were treated with serial dilutions of dexamethasone to determine a concentration to 
be used that is well in the maximal signal range. .  Y-Axis is the Inner/Outer ratio calculated by 
dividing the Inner (nucleus) intensity by the Outer (cytoplasm) intensity.  Error bars are in 
standard deviation. Data is representative of three separate experiments run three separate days.  
All treatments were run in triplicate. 
 
 
 
 
 
 
B. Test Cytoplasmic Dynein, Hsp90, Hsp70 Inhibitors and Microtubule Perturbagens 
The original focus of this project was to identify novel cytoplasmic dynein inhibitors.  In 
2012 the first selective inhibitors of cytoplasmic dynein were published (5).  These compounds 
were named ciliobrvin A and D, because cells that are treated with them have shortened 
cilia(17).  To test these inhibitors in the translocation assay the 3617.4 cells were treated with 
ciliobrevin A and D (purchased from Tocris, Bristol, UK).  The results from these experiments  
are shown in Figures 8 and 9.  Figure 8B compares the average inner intensity (nucleus) to the 
average outer intensity (Figure 8C) (cytoplasm) of the GFP signal in the GR translocation assay 
after treatment with the  dynein inhibitors ciliobrevin A and D at 100µM, 75µM, 50µM, 25µM 
and 12.5µM for one hour prior to dexamethasone addition.  Initially the inner/outer intensity 
ratio appeared to decrease due to increasing ciliobrevin concentrations, implying that the 
inhibition of GR translocation was successful when cells are treated with the ciliobrevins (Figure 
8A). However, ciliobrevin A was cytotoxic (Figure 8A) and both compounds appear to fluoresce 
in the GFP channel (Figure 9).  Their average outer intensity is equal to or higher than the 
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negative control and their average inner intensity is also equal to or higher than the positive 
control (Figure 8B).  This was confirmed when cells that were still being treated with 
tetracycline, not producing GFP, were exposed to the compounds and there was an increase in 
fluorescence that appears to be concentration-dependent (Figure 9).  This means that 
unfortunately the ciliobrevins could not be used to show proof of concept that small-molecule 
inhibitors of cytoplasmic dynein would inhibit Dex-induced GR-GFP translocation. 
 
A 
 
B 
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Figure 8: Inner/Outer Ratio and Average Outer and Inner Intensity of GFP in 3617.4 Cells 
Treated with Cytoplasmic Dynein Inhibitors 
      Cells were pre-treated with dynein inhibitors for one hour before the addition of 100nM 
dexamethasone.  (A) Inner/outer ratio and cell counts. Average outer and inner intensity (B&C)  
Neg = negative control (no dex); Pos = positive control (dex treated); D = Ciliobrevin D 
(concentration 12.5, 25, 50, 75, 100µM; A= Ciliobrevin A (Concentrations 12.5, 25, 50, 75, 
100µM).  The graph title describes the Y-axis. Error bars are in standard deviation.  Each 
treatment was completed in triplicate. Results depicted here are representative of three separate 
experiments carried out three separate days. 
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Figure 9: Average Outer and Inner Intensity of GFP Channel of 3617.4 Cells Treated With 
Cytoplasmic Dynein Inhibitors With No GFP 
Best results of three separate experiments over three separate days 
Error bars in standard deviation 
0 = No compound added; D = Ciliobrevin D (concentration 12.5, 425, 50, 75, 100µM (5, 4, 3, 
2,1 respectively)); A= Ciliobrevin A (Concentrations 12.5, 25, 50, 75, 100µM (5, 4, 3, 2,1 
respectively)); RFU = Relative Fluorescence Units. 
 
 
 
 
 
 
 After the dynein inhibitors failed to show proof of concept, it was decided to test other 
possible inhibitors of GR-translocation in the GR translocation assay to determine a target where 
proof of concept could be shown..  Figure 10 shows the results of testing microtubule 
perturbagens, hsp90, and hsp70 inhibitors in the GR translocation assay.  None of the 
microtubule perturbagens had an apparent effect on GR translocation (Figure 10), which is 
consistent with published results that suggest that not only is the GR transported to the nucleus 
via cytoplasmic dynein, but there may be alternate microtubule-independent routes (8).  The 
novel hsp70 inhibitor MAL3-101also did not have any effect on GR translocation (Figure 10A).  
Consistent with the original assay development studies (9, 10), both the hsp90 inhibitors 17-
AAG and STAT9090 inhibited Dex-induced GR-GFP nuclear translocation (Figure 10A). 
Fluorescent images of cells treated for one hour with STA9090 and paclitaxel prior to the 30 
minute treatment with dexamethasone are represented in Figure 10B.  The image of the cells 
treated with STA9090 are consistent with the image of the cells in Figure 4A, confirming that 
STA9090 inhibits GR translocation.  Conversely, the image of the cells treated with paclitaxel 
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are consistent with the image of the cells in Figure 10B, confirming that paclitaxel does not 
inhibit GR translocation.   
  
 
 
A 
B 
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Figure 10:  3617.4 Cells Treated With Microtubule Perturbagens, Hsp90, and Hsp70 
Inhibitors. 
Best results of three experiments over three separate days.  Error bars in std dev. 
 
2.5 DISCUSSION 
When optimizing the GR-GFP translocation assay the first step was to show that in the 
presence of dexamethasone the GFP co-localizes with the nucleus and without dexamethasone 
treatment the GFP stays in the cytoplasm.  This is demonstrated in the images presented in 
Figure 4.  The results suggested that it does not make a difference as to whether the cells are 
fixed and then aspirated or aspirated and then fixed after the dexamethasone treatment (Figure 
5).  Based on these results it was concluded that the cells adhere tightly to the wells and the 
method used for aspiration does not create enough force to detach them from the wells.  To be 
consistent with the original screening assay protocol it was decided to aspirate the wells and then 
fix the cells (9).   Based on the results, it was then determined that the cells should be treated 
with 100nM dexamethasone in order to achieve maximal translocation of the GR-GFP to the 
nucleus.  100nM dexamethasone is far enough into the signal plateau that small variations in 
dexamethasone concentration due to error should not affect the results.   These results were 
consistent with the published results from the original assay development and optimization 
manuscript (9). 
 Once the conditions for the GR-GFP translocation assay were determined it was 
necessary to show a proof of concept that inhibition of dynein by a small-molecule would in fact 
inhibit the translocation of the GR-GFP in this cell-based assay.  Unfortunately the data showed 
that the published dynein inhibitors actually fluoresce in the GFP channel thereby confounding 
the interpretation of the data (Figures 8 & 9).  Based on  these data it was determined that the 
best course of action would be to test hsp90 and hsp70 inhibitors and microtubule perturbagens 
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in the GR-GFP translocation assay.  Consistent with previous publications both hsp90 inhibitors, 
17-AAG and STAT9090, inhibited  Dex-induced GR-GFP translocation to the nucleus (9, 10).  
Conversely, the hsp70 inhibitor MAL3-101 did not inhibit translocation nor did the microtubule 
perterbagens (Figure 10).   
 Inhibition of hsp70 did not inhibit translocation most likely due to the fact that hsp70 is 
involved in earlier steps of the maturation of the GR (12).  Once hsp90 is bound and opens the 
LBD of the GR most of the hsp70 bound to the complex detaches (11).  For an hsp70 inhibitor to 
inhibit GR translocation the inhibitor would need to be added to the cells at the same time that 
the tetracycline is removed.  The 3617.4 cell line utilizes a tet-off system to suppress GR-GFP 
transcription.  Inhibition of hsp70 at that point would be expected to hinder GR maturation and 
import of hsp90 to the complex.  This experiment should be performed  in future studies. 
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3.0 CHARACTERIZATION OF HIT COMPOUNDS 
 
3.1 INTRODUCTION 
From the original HCS in the GR translocation assay, 112 hit compounds with IC50s of ≤ 
10µM (chosen because 10µM  was determined to be a good potency cut off for the following 
analyses) were found to inhibit GR translocation from a library of approximately 220,000 
compounds. To reduce the number of hit compounds to be further tested for their ability to 
selectively inhibit hsp90, the compounds were analyzed for: their biological promiscuity using 
PubChem; a PAINS (25) search database created by Dr. Xiangqun Xie’s laboratory at the 
University of Pittsburgh;, drug-like properties in a medicinal chemistry analysis using Instant 
JChem from Chem Axon; and a small-molecule docking simulation using the SYBYL software 
from Certara.    
PubChem is a database created and updated by the National Institutes of Health (NIH) 
that allows users to perform queries to bring back compound information including physical 
properties and activity in biological assays (24).  The PAINS search database allows users to 
search for possible assay interferences and promiscuity of the compound based on structures and 
functional groups known to interact with non-specific proteins (25).  SYBYL is software that 
utilizes protein data bank (PDB) files of x-ray crystal structures of proteins to allow the user to 
identify binding pockets on the protein and simulate binding of compounds (27).  The user can 
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set the simulation to identify a pocket on the crystal structure of the protein as the binding site to 
be tested against a compound library.  The algorithm in SYBYL will search for possible 
interactions between the binding pocket and each compound. This generates a docking score that 
helps the user predict the likelihood that a given compound will bind the programmed binding 
pocket on the protein being analyzed.  A medicinal chemistry analysis was done in order to 
evaluate the drug-like properties of the compounds.  By inputting the simplified molecular-input-
line-entry system (SMILES) structure of compounds into the Instant JChem this generates values 
for the LogP, Total polar surface area, hydrogen-bond acceptor, hydrogen-bond donor, rotatable 
bonds, lead likeness, Lipinski Rule of 5 (pass or fail) Rule of 3 (pass or fail), Veber Filter (pass 
or fail),  and Muegge filter (pass or fail). This aids in determining whether a compound is a good 
candidate for further drug development. 
The Log P, total polar surface area, hydrogen-bond acceptors, hydrogen-bond donors, 
rotatable bond, lead likeness, and the Lipinski Rule of 5 were all used under their basic 
definitions (37, 38).  The Rule of 3 is a set of rules for lead-like compounds that may be 
fragments that can be expanded upon during the lead optimization process and includes: 
molecular weight ≥ 300, Clog P (LogP based on structure) ≤ 3, rotatable bonds ≤ 3, hydrogen-
bond donors ≤ 3, hydrogen-bond acceptors ≤  3, and polar surface area  ≤  60 angstroms 
squared(38).    The Veber Rule determines good bioavailability in rats and is based on molecular 
flexibility, polar surface area, and hydrogen bonding (38).  The Veber Rule identifies compounds 
with rotatable bonds ≤ 10 and polar surface area ≤ 140 angstroms squared or total hydrogen 
bonds (acceptors plus donors) ≤ 12 (38).  The Muegge filter identifies compounds that have 
molecular weight < 500, CLogP < 5, and a polar surface area < 120 angstroms squared and only 
includes compounds that contain C, N, O, S, H, P, Cl, Br, F, I, Na, K, Mg, Ca, and Li (41). This 
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filter also identifies compounds that have combinations of two pharmacophore points which are 
functional groups that include: amine, amide, alcohol, ketone, sulfone, sulfonamide, carboxylic 
acid, carbamate, guanidine, amidine, urea, and ester.  Lastly, compounds that contain structures 
with know toxicities are removed (41). 
 
3.2 SPECIFIC AIM 
The goal of these simulations was to evaluate whether any of the GR-GFP translocation 
inhibitor  hits might be  hsp90 inhibitors.  
 
 
3.3 METHODS 
Pubchem Search 
 The substance identification numbers (PubChem SIDs) of hit compounds with IC50s of 
10µM or less were entered into the PubChem query.  The number of active, inactive, 
inconclusive, unspecified, and total flags (total number of bioassays each compound was tested 
in) were extracted from the “biological test results” section.  The number of active flags 
(bioassays in which the compound was designated active) was divided by the total number of 
bioassays the substance has been tested in to give the percent active flags.  Compounds were 
categorized by < 5%, 5-8%, 10-15%, and greater than 15% active flags.  Active flags is 
described as the number of targets that the compound was found to have activity against in a 
biological assay.   
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PAINS Search 
Compound SMILES were collected from the PubChem website.  The SMILES were 
entered into the search window on the PAINS website from the Xie lab.  The database would 
then output whether the compound was a PAINS compound or not (25).  This model compares 
the structures of the compounds to known compound structures that have been found to be 
PAINS compounds. 
Medicinal Chemistry Analysis 
Instant JChem was set to give outputs for LogP, Total polar surface area, hydrogen-bond 
acceptor, hydrogen-bond donor, rotatable bonds, lead likeness, Lipinski Rule of 5, Rule of 3, 
Veber Filter, and Muegge filter. SMILES were entered into Instant JChem and the software then 
calculated the values for all parameters.  Once these values were acquired the structures of the 
compounds were analyzed to remove those compounds that were highly reactive and/or possibly 
toxic.  Once all these results were combined, compounds that best fit the set criteria  described 
above were picked to be further analyzed. 
SYBYL Docking Simulation 
The PDB file 1A4H (a co-crystal structure of yeast hsp90 and geldanamycin) was 
acquired from the RCSB Protein Data Bank (www.rcsb.org).  Water was removed from the file 
and hydrogens were added to the structure.  Geldanamycin was removed from the crystal 
structure and the pocket were geldanamycin was bound was identified as the binding pocket, 
which is the ATP binding site.  A SMILE (.smi) file was created using the SMILES from the hit 
compounds. This file was then loaded as the ligand source and the docking simulation was run in 
the Surflex-Dock Screen docking mode. 
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Figure 11:  ATP and Geldanamycin Binding Hsp90 
Geldanamycin is a natural product from Steproyces bacteria.  It was the first reported inhibitor of 
hsp90.  Geldanamycin binds the ATP-binding site of hsp90, thus blocking the binding of ATP 
and inhibiting the conformational changes needed for hsp90’s chaperone function.  The right 
image is from the PDB 1yet, the left image is from PDB 1am1.  This binding site was used in the 
SYBYL docking simulation described in this thesis as the binding pocket to generate binding 
scores if the hit compound list. Image acquired from pdb.org Molecule of the Month and 
duplicated freely under the CC-BY-3.0 license (42) 
 
 
3.4 RESULTS 
65 compounds, from the original 112, with active flags of 0-10% (Table 1) were further 
analyzed for PAINS, medicinal chemistry properties, and SYBYL docking of hsp90.  Seven 
were found to be possible PAINS compounds; indicated with (*) in Table 1.  The most common 
targets that were identified for the compounds were the dopamine receptor D2 (DRD2), tissue-
nonspecific alkaline phosphatase  (ALPL), induced myeloid leukemia cell differentiation protein 
(MCL1), acid alpha-glucosidase (GAA), and peroxisome proliferator-activated receptor gamma 
(PPARG). 
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Pubchem SID GR-GFP HCS IC50 uM Total Flags % Active Flags Targets 
26725277* 9.4 561 2.1 Trpc6,VDR,NFE2L2,DRD2,Trpc4 
14729341 1.5 670 2.5 DRD2, ALPL, GAA, MCL1, MPI 
24810875 6.2 605 2.8 MCL1,GAA,ALPL,PPARG,DRD2 
26725379 9.7 550 2.9 CHRM5,CHRM4,CHRM1,RGS4,DRD2 
24835144 6.0 504 3.0 MPI,GAA,ALPL,PPARG,DRD2 
26659974 3.7 568 3.0 DRD2, RGS4, CHRM1, CHRM4, CHRM5 
24812564 3.8 513 3.1 DRD2, ALPL, GAA, MPI, PPARG 
24832777 10.0 532 3.2 RGS4,MPI,ALPL,PPARG,DRD2 
24836477 4.5 495 3.2 DRD2, PPARG, ALPL, GAA, MPI 
26659438 7.3 569 3.3 CHRM4,CHRM1,CFTR,RGS4,DRD2 
26731745 9.0 478 3.3 CHRM4,CHRM1,TIM10,RGS4,DRD2 
26663384 5.9 562 3.4 RGS4,CFTR,SLC5A7,NFE2L2,DRD2 
24837780 7.8 638 3.6 GAA,CFTR,ALPL,PPARG,DRD2 
24808613 8.6 459 3.9 MPI,ALPL,PPARG,DRD2,TNFRSF10B 
14731316 8.6 685 4.2 MPI,MCL1,GAA,ALPL,DRD2 
24793559 8.2 631 4.3 MCL1,GAA,ALPL,PPARG,DRD2 
24808536 6.8 551 4.4 CFTR,ALPL,Hsf1,PPARG,DRD2 
24831419 8.5 637 4.7 MC4R,GAA,ALPL,PPARG,DRD2 
24708194 2.8 603 4.8 DRD2, ALPL, GAA, MCL1, MPI 
17508477 3.9 672 5.1 MRGPRX1, DRD2, SLC5A7, ALPL, GAA 
26664573 7.4 573 5.2 CHRM1,NLRP3,RGS4,CFTR,DRD2 
24821616 7.2 540 5.4 MPI,DRD2,ALPL,PPARG,MITF 
24789826 8.9 640 5.5 MCL1,GAA,ALPL,DRD2,MITF 
14732770* 2.0 698 5.6 RGS4, MRGPRX1, ALPL, CFTR, DRD2 
24785468 9.5 643 5.6 GAA,ALPL,PPARG,DRD2,RGS4 
26725810 4.7 569 5.6 DRD2, RGS4, CFTR, CHRM1, CHRM4 
17510018* 8.3 547 5.9 ALPL,NFE2L2,PPARG,DRD2,MITF 
24830204 9.3 647 6.5 ALPL,PPARG,DRD2,MRGPRX1,MITF 
22406089 6.9 661 6.5 TP53,GALR2,DRD2,CFTR,MITF 
24827565 4.0 641 6.6 ALPL, CFTR, GAA, MCL1, MPI 
24811325 4.2 625 6.6 TNFRSF10B, DRD2, ALPL, GAA, MPI 
17513591 4.2 639 6.7 MRGPRX1, DRD2, ALPL, CFTR, GAA 
17504722 7.8 664 6.8 MPI,GAA,ALPL,MCL1,CFTR 
17514011 0.6 515 7.0 DRD2, Trpc4, ALPL, GAA, KCNQ1 
22409186 9.0 510 7.1 MCL1,GAA,ALPL,PPARG,DRD2 
24820374 1.6 376 7.2 PPARG, ALPL, GAA, MCL1, MPI 
24821031 0.9 583 7.4 GNAO1, PPARG, ALPL, MPI, MAP4K2 
17387987 5.4 702 7.4 DRD2, JAK2, TIM10, ALPL, GAA 
24817684 7.4 554 7.6 MPI,GAA,ALPL,DRD2,MITF 
17413916 8.6 691 7.7 GAA,ALPL,VDR,DRD2,RGS4 
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14739918 6.6 704 7.8 GAA,ALPL,Kcnq2,KCNQ1,DRD2 
22408535 6.6 665 7.8 MCL1,GAA,ALPL,SLC5A7,DRD2 
22403487 8.0 651 8.0 ALPL,PSIP1,MCL1,DRD2,MITF 
24830158 8.9 571 8.4 ALPL,PPARG,Kcnq2,KCNQ1,DRD2 
17509721 9.7 593 8.4 MCL1,GAA,ALPL,DRD2,TNFRSF10B 
24812054 9.6 592 8.4 MCL1,GAA,ALPL,PPARG,DRD2 
24818889 4.6 561 8.6 MITF, DRD2, Hsf1, ALPL, GAA 
24819034 8.6 647 8.7 ALPL,ADRB2,KCNQ1,IDH1,DRD2 
14743736 9.2 707 8.9 MCL1,GAA,ALPL,DRD2,MRGPRX1 
24826599* 9.5 670 9.0 KCNQ1,FXN,HKDC1,DRD2,MITF 
24803246 8.4 566 9.0 MPI,GAA,ALPL,DRD2,TNFRSF10B 
22408394 6.6 655 9.2 GAA,ALPL,PPARG,DRD2,MITF 
17517377 6.8 683 9.2 GAA,ALPL,DRD2,MITF,TNFRSF10B 
24841212 9.0 579 9.3 GAA,ALPL,DRD2,MITF,TNFRSF10B 
17412468 5.0 686 9.3 DRD2, MCL1, ALPL, GAA, MPI 
14743646 9.4 711 9.4 MCL1,GAA,ALPL,DRD2,RGS4 
17402075 1.5 711 9.6 MRGPRX1, DRD2, MCL1, ALPL, GAA 
17387926* 3.8 657 9.6 DRD2, ALPL, GAA, MCL1, MPI 
24809046 8.0 465 9.7 RGS4,PPARG,MPI,ALPL,DRD2 
24809046 8.0 465 9.7 RGS4, MPI,ALPL,PPARG 
22404816 3.0 587 9.7 CXCR6, ALPL, DRD2, GAA, MPI 
26725671* 7.0 582 9.8 CHRM1,TIM10,Alpi,DRD2,RGS4 
849046 1.5 826 9.9 Trpc4, ALPL, DRD2, SLC5A7, RGS4 
24785301 8.8 573 9.9 MPI,GAA,DRD2,ALPL,Kcnq2 
17403527* 0.6 472 10.0 GNAO1, MAP4K2, ALPL, GAA, MCL1 
  
TABLE 1: 65 compounds from PubChem search that were found to have 0-10% active 
flags.  
Compounds are identified by their substance identification number (SID).  The number of flags 
refers to the number of reported active designations  in biological assays. (*) compounds are 
compounds that were found to be PAINS in the PAINS database search. 
 
 
The 65 compounds from the PubChem search were analyzed for drug-like and lead-like 
properties in a medicinal chemistry analysis using Instant JChem and then further analyzed for 
reactivity, possible toxicity, and ease of synthesis, which are important for drug development.  
The results from the analysis are shown in Table 2.  Based on the SMILES of each compound, 
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Instant JChem produced values for LogP, total polar surface area, hydrogen-bond acceptor, 
hydrogen-bond donor, rotatable bonds, lead likeness, Lipinski Rule of 5, Rule of 3, Veber Filter, 
and Muegge filter.   Acceptable LogP values were 1-5 with 1-4 being preferred.  Compounds 
with LogP values in this range are good drug-like candidates because they are likely to be orally 
absorbed and distributed through the blood stream.  They will be hydrophobic enough to 
partition into the lipid bilayer, but not so hydrophobic that they stay in the lipid bilayer.    Total 
polar surface area values of 120-122 angstroms squared were acceptable, however values below 
120 angstroms squared were preferred.  Hydrogen-bond acceptors of 0-10 were considered 
acceptable with 1-6 being preferred.  Hydrogen-bond donors of 0-5 were considered acceptable 
with 1-5 being preferred.  Compounds having 0-10 rotatable bonds were considered acceptable 
with 0-8 being preferred.  Meeting three of the four Lipinski Rule of 5 was a pass whereas the 
Veber filter, Muegge filter, and the Rule of 3 where a pass if all parameters were met and a fail if 
a single parameter was not met.   A majority of drugs that have made it to the market possess 
these properties (37-41). 
Results Formula SID MW LogP TPSA HBA HBD RB Lead likeness 
Lipinski 
rule of 5 
(3 of 4) 
Veber 
filter 
Rule of 
3 
Muegge 
filter 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C12H10 
BrN3O3 14729341 324.13 2.44 78.03 4 0 4 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C12H9 
BrN4O5 24810875 369.13 2.38 121.2 6 0 5 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C13H12 
BrN3O4 26659974 354.16 2.28 87.26 5 0 5 TRUE TRUE TRUE FALSE TRUE 
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NO2 
flag No 
H bond 
donors 
yet 
potent 
C12H9 
BrFN3 
O3 
24812564 342.12 2.58 78.03 4 0 4 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C11H10 
BrN3O2 26663384 296.12 2.93 60.96 3 0 3 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C12H9Br
2N3O3 14731316 403.03 3.21 78.03 4 0 4 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag 
C10H13 
N5O4 26725810 267.24 1.10 110.4 5 1 3 TRUE TRUE TRUE FALSE TRUE 
 NO2 
flag 
C14H17 
N3O4S 17387987 323.38 3.36 95.1 5 0 6 TRUE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C10H8Cl
N3O4S 22404816 301.71 2.26 95.1 5 0 3 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
C13H16 
ClNO 24835144 237.73 2.67 20.31 1 0 2 TRUE TRUE TRUE TRUE TRUE 
a-halo 
ketone 
C11H11 
ClN2O2 24832777 238.67 1.69 48.03 2 0 3 TRUE TRUE TRUE TRUE TRUE 
a-halo 
amide 
C16H23 
ClN2O 24836477 294.82 2.77 23.55 2 0 4 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
C12H16 
ClNO2 24837780 241.71 1.88 29.54 2 0 5 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
C12H13 
ClFNO 24808613 241.69 2.66 20.31 1 0 1 TRUE TRUE TRUE TRUE TRUE 
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a-halo 
ketone 
C12H13 
ClN2O2 24830204 252.70 1.71 48.03 2 0 3 TRUE TRUE TRUE TRUE TRUE 
a-halo 
amide 
C8H9Cl2
NOS 24827565 238.13 2.36 20.31 1 0 3 TRUE TRUE TRUE TRUE TRUE 
a-
haloami
de 
C21H23 
ClFN3O2 17509721 403.88 3.17 62.3 3 1 6 TRUE TRUE TRUE FALSE TRUE 
a-halo 
ketone 
C13H11C
lFN3O 24819034 279.70 2.04 53.49 4 2 5 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
remove 
C17H14 
ClN3O 14743736 311.77 3.96 46.92 2 1 4 TRUE TRUE TRUE FALSE TRUE 
a-halo 
ketone 
C15H16 
ClNO2 24826599 277.75 2.24 31.23 2 0 4 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
remove 
C15H12 
Cl2N2O3 24803246 339.17 3.88 63.45 3 0 5 TRUE TRUE TRUE FALSE TRUE 
a-halo 
amide 
remove 
C14H13 
ClN2O2S 17517377 308.78 2.61 45.81 2 0 3 TRUE TRUE TRUE FALSE TRUE 
fragment
/No H-
Bonds/ 
possible 
reactive 
nucleous 
C10H12C
l2N2 
O2 
24821616 263.12 2.60 49.74 3 0 3 TRUE TRUE TRUE TRUE TRUE 
fragment
/No H-
Bonds/ 
possible 
reactive 
nucleous 
C11H7Cl
2FN2O 24789826 273.09 2.86 32.67 2 0 2 TRUE TRUE TRUE TRUE TRUE 
 possible 
reactive 
nucleous 
flag 
C17H18C
l2N4O3 22406089 397.26 1.98 82.08 4 1 6 TRUE TRUE TRUE FALSE TRUE 
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fragment
/No H-
Bonds/ 
possible 
reactive 
nucleous 
C13H12C
l2N2O 22409186 283.15 3.74 32.67 2 0 2 TRUE TRUE TRUE FALSE TRUE 
No-H 
bond 
donors/ 
fragment
/possible 
reactive 
nucleous 
C10H12B
r2N2O2 24817684 352.02 2.93 49.74 3 0 3 TRUE TRUE TRUE FALSE TRUE 
 possible 
reactive 
nucleous 
flag 
C14H12C
l2F3N3 
O2 
22408535 382.17 2.88 54.67 3 0 5 TRUE TRUE TRUE FALSE TRUE 
 possible 
reactive 
nucleous 
flag 
C15H15C
l2N3O2 22403487 340.21 2.66 54.67 3 0 5 TRUE TRUE TRUE FALSE TRUE 
Aliphati
c ketone 
flag/ 
fragment
/no H-
bonds, 
posibble 
reactive 
nucleous 
flag 
C7H6Br2
N2O2 24818889 309.94 1.13 49.74 3 0 2 TRUE TRUE TRUE FALSE TRUE 
 possible 
reactive 
nucleous 
flag 
C16H16C
l2N4O3 22408394 383.23 1.54 82.08 4 1 5 TRUE TRUE TRUE FALSE TRUE 
possible 
reactive 
nucleous 
flag 
C14H10C
l2N4O3 24841212 353.16 0.71 82.08 4 1 2 TRUE TRUE TRUE FALSE TRUE 
ab 
conjugat
ed cyano 
possible 
flag, 
high log 
P 
C21H16C
lN3OS 17513591 393.89 5.62 65.78 3 1 4 FALSE TRUE TRUE FALSE FALSE 
ab 
conjkuga
ted 
cyano, 
possible 
flag, 
high log 
P 
C21H15C
l2N3OS 17514011 428.33 6.22 65.78 3 1 4 FALSE TRUE TRUE FALSE FALSE 
Posible 
reactive 
nucleous
, High 
logP 
C18H13B
rN4S 17412468 397.29 5.00 61.6 4 1 4 FALSE TRUE TRUE FALSE TRUE 
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OK C24H22N2O 17387926 354.44 4.82 59.04 3 1 2 FALSE TRUE TRUE FALSE TRUE 
Not sure 
Maybe 
OK 
C24H21C
lN2O5 24820374 452.89 4.40 93.73 4 2 7 FALSE TRUE TRUE FALSE TRUE 
Not sure 
Maybe 
OK 
C28H22N
2O6 24821031 482.48 4.27 102.96 4 2 9 FALSE TRUE TRUE FALSE TRUE 
fragment C7H5NOS 24830158 151.19 1.36 29.1 1 1 0 TRUE TRUE TRUE TRUE FALSE 
fragment C7H4FNOS 24785301 169.18 1.50 29.1 1 1 0 TRUE TRUE TRUE TRUE FALSE 
ab-
conjugat
ed 
C19H20 
O4 26725277 312.36 3.51 63.6 4 1 4 TRUE TRUE TRUE FALSE TRUE 
vinilogo
us amide 
maybe 
issue 
C17H14B
rClN2O 14732770 377.66 4.70 41.13 3 2 3 FALSE TRUE TRUE FALSE TRUE 
ab 
conjugat
ed 
remove 
C18H17N
O2 24785468 279.33 4.00 46.17 2 1 4 FALSE TRUE TRUE FALSE TRUE 
curcumi
n type 
remove 
C20H21N
3O 17510018 319.40 2.62 46.09 4 0 3 TRUE TRUE TRUE FALSE TRUE 
maybe 
OK 
C17H13N
O3 24811325 279.29 3.03 47.89 3 0 3 TRUE TRUE TRUE FALSE TRUE 
ab 
conjugat
ed 
remove 
C20H30 
O5 17504722 350.45 0.50 97.99 5 4 0 TRUE TRUE TRUE FALSE TRUE 
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a,b 
conjugat
ed nitro, 
high 
NRB 
C16H19N
O8 17413916 353.32 1.78 114.2 6 0 12 FALSE TRUE FALSE FALSE TRUE 
no H-
bonds 
High 
NRB 
C15H25N
O7 14739918 331.36 0.62 91.37 5 0 11 FALSE TRUE FALSE FALSE TRUE 
No H-
bonds 
flag, 
C9H6Cl 
N5 24812054 219.63 2.33 55.97 4 0 0 TRUE TRUE TRUE FALSE TRUE 
redox C22H18N2O4S 14743646 406.45 2.82 76.66 6 2 5 TRUE TRUE TRUE FALSE TRUE 
OK C16H10F3N5OS3 17402075 441.47 4.31 93.79 5 2 4 TRUE TRUE TRUE FALSE TRUE 
MW too 
high/red
ox fag 
C31H27N
3O6 26725379 537.56 4.13 107.92 8 0 9 FALSE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C12H8N6
O2S 24809046 300.30 3.20 99.63 6 0 4 TRUE TRUE TRUE FALSE TRUE 
Same as 
compou
nd 
above, 
NO2 
flag, No 
H bond 
donors 
yet 
potent 
C12H8N6
O2S 24809046 300.30 3.20 99.63 6 0 4 TRUE TRUE TRUE FALSE TRUE 
redox C16H11N3O6S 26725671 373.34 2.53 118.85 6 1 4 TRUE TRUE TRUE FALSE TRUE 
too 
simple, 
LogP 
high 
highly 
lipophili
c 
C14H22 
O2 849046 222.32 5.06 40.46 2 2 6 FALSE TRUE TRUE FALSE FALSE 
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Highly 
conjugat
ed 
positivel
y 
charged 
C21H21I
N2OS 17403527 476.37 0.04 24.19 1 0 5 FALSE TRUE TRUE FALSE TRUE 
NO2 
flag No 
H bond 
donors 
yet 
potent 
C15H20O
4 26731745 264.32 2.50 44.76 4 0 9 TRUE TRUE TRUE FALSE TRUE 
ab 
conjugat
ed 
remove 
C18H16C
lNO5S 24793559 393.84 5.25 92.7 4 2 7 TRUE TRUE TRUE FALSE FALSE 
alkyl-
halide 
C15H19C
lO4S 24808536 330.83 3.40 52.6 2 0 10 TRUE TRUE TRUE FALSE TRUE 
OK C18H26N4O4 24831419 362.42 1.96 93.65 6 1 8 TRUE TRUE TRUE FALSE TRUE 
maybe 
OK but 
not a 
lead 
MW 
high 
C28H28N
2O6 24708194 488.53 2.76 101.06 5 0 8 FALSE TRUE TRUE FALSE TRUE 
OK but 
not lead 
like 
C21H17N
3OS 17508477 359.44 4.84 59.22 3 1 1 FALSE TRUE TRUE FALSE TRUE 
ab 
conjugat
ed 
remove 
C12H11N
O6 26664573 265.22 2.42 95.74 4 0 6 TRUE TRUE TRUE FALSE TRUE 
    26659438 0   0 0 0 0 FALSE TRUE TRUE FALSE FALSE 
  
Table 2:  Results from Med Chem Analysis using Instant Jchem.   
Parameters were set in Instant JChem to determine drug-likeness and Lead-likeness. Other 
considerations were functional groups and reactivity. Green indicates that the parameter passed 
the criteria, Yellow indicates that the parameter value is mostly passed, and Red indicates that 
the parameter failed the criteria. 
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CID Total_Score Notes 
24708194 7.57   
24821031 7.33   
849046 6.99   
17510018 6.49  PAINS 
26731745 6.07   
22406089 5.84   
24793559 5.82   
24808536 5.79   
14743646 5.76   
24820374 5.67   
22408394 5.62   
24785468 5.57   
24819034 5.53   
17403527 5.53   
26725379 5.52   
24831419 5.40 Ok Med Chem Analysis 
24837780 5.37   
17413916 5.36   
24831419 5.23   
14732770 5.22   
17514011 5.20   
17387987 5.12   
14739918 5.08   
17513591 4.98   
26725671 4.94   
24830204 4.84   
26659974 4.80   
26664573 4.80   
24826599 4.66   
24812564 4.64   
22408535 4.53   
24841212 4.45   
24803246 4.40   
22404816 4.37   
26663384 4.36   
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22403487 4.33   
24785301 4.18   
24810875 4.18   
24811325 4.17   
26725810 4.17   
24836477 4.14   
24835144 4.14   
17412468 4.06   
17509721 4.00   
14731316 3.81   
22409186 3.70   
24817684 3.55   
17387926 3.50   
24832777 3.28   
24809046 3.22   
24809046 3.22   
24830158 3.21   
24821616 3.19   
17504722 3.11   
17517377 3.09   
24789826 3.06   
24818889 3.00   
17508477 2.94   
24808613 2.84   
14743736 2.68   
17402075 2.52 Ok Med Chem Analysis 
24827565 2.13   
24812054 1.55   
Table 3:  Docking Scores from SYBYL Docking Simulation.   
The 5 compounds highlighted in yellow have a high likelihood of binding yeast hsp90 at the 
geldanamycin binding site.  Compounds highlighted in green were found to have favorable drug-
like properties in the medicinal chemistry analysis.  
 
 
 Selected hit compounds from the PubChem analysis were docked against the 
geldanamycin binding site, results can be found in Table 3.  Compounds with a score of 6 or 
greater (based on the parameters created by the Xie lab, School of Pharmacy, University of 
Pittsburgh, in this SYBYL docking simulation) were determined to have a high probability of 
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binding yeast hsp90 at the geldanamycin binding site, these compounds are highlighted in yellow 
(a score of 6 means µM binding).  One of these compounds, 17510018, was found to be a PAINS 
compound. Compounds that were found to have favorable drug-like properties in the medicinal 
chemistry analysis are noted in Table 3. 
 
 
3.5 DISCUSSION 
The result of these analyses and simulations was the prioritization of five compounds for 
further investigation (Table 4).  For the purpose of this study when identifying a small-molecule 
inhibitor of a protein it is also important that the small-molecule is selective for the protein 
target.   A compound that is not selective for a protein target has the potential to produce 
negative side effects in a clinical setting.  The PubChem search, coupled with the PAINS 
database search, identified hit compounds that have low promiscuity, i.e. compounds that are not 
a PAINS compound and have less than 8% active flags.  
Once compounds with low promiscuity were identified it was necessary to predict 
whether a given compound would bind hsp90.  Compounds with SYBYL docking scores of six 
or greater using this docking model have an increased probability of binding hsp90.  It is also 
important to take into consideration whether the compound is drug-like, i.e. has acceptable 
pharmacokinetic properties.  
Table 4 shows the results of each test for the five compounds selected from the original 
112 hit compounds with translocation IC50s < 10 μM.  The first two compounds were chosen 
based on their SYBYL docking score ratings being 1 and 2, respectively, indicating a higher 
probability of binding hsp90 in the geldanamycin binding pocket when compared to the rest of 
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the 65 hit compounds, narrowed down from the 112 hit compounds.  These compounds also 
appear to have low promiscuity, based on the PubChem search, they have 4.8% and 7% active 
flags, respectively, and were not PAINS compounds.  In the medicinal chemistry analysis both 
compounds passed most of the test criteria.   Both compounds have molecular weights 
approaching 500, the maximum molecular weight for a drug-like compound according to the 
Lipinski rule of 5.  This leaves little room for lead optimization if functional groups are added.  
Although a disadvantage compound 24708194 is the lack of hydrogen-bond donors, hydrogen 
bond donors can be added and the compound still has five hydrogen bond acceptors.  Compound 
24821031 has excellent hydrogen bonding capabilities with four hydrogen-bond acceptors and 
two hydrogen-bond donors.  A drawback for compound 24821031 is its LogP value of 4.27, a 
moderately high value indicating poor aqueous solubility. Additionally the number of rotatable 
bonds is moderately high at nine.  Overall these two compounds are good candidates due to high 
docking scores and for the most part have ideal drug-like properties.   Two other compounds, 
17402075 and 24831419, were selected as both passed all of the parameters in the medicinal 
chemistry analysis.  They both show low promiscuity through the PubChem search and were not 
found to be PAINS compounds.  The fifth compound was selected even though it was found to 
be a possible PAINS compound, however the PubChem search only came up with 1.3% active 
flags.  This compound could possibly give some insight into which method is more reliable to 
determine promiscuity, the PAINS database or the PubChem search. 
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 TABLE 4:  The 5 hit compounds selected to be further characterized as hsp90 inhibitors  
SID = Substance Identification Number 
 
 
Figure 12:  Structures of Selected Hit Compounds 
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4.0 ATPASE ACTIVITY ASSAY 
4.1 INTRODUCTION 
The original HCS, which involved the translocation of the GR, and the subsequent 
cheminformatics analysis has identified hit compounds that might be  inhibitors of the ATPase 
activity of  hsp90.  To test these compounds the PiPer assay from Invitrogen, which is an enzyme 
coupled amplex red assay, was used to detect ATPase activity of recombinant yeast hsp90. The 
PiPerTM assay is an enzyme-coupled assay that measures inorganic phosphate production by an 
ATPase (as well as phosphate produced by phosphatases).   ATPase’s produce inorganic 
phosphate by hydrolyzing ATP.  The 1st coupling enzyme Maltose phosphorylase catalyzes the 
phosphorylation of maltose to produce glucose 1-phosphate and glucose.  The 2nd coupling 
enzyme Glucose oxidase then catalyzes the oxidation of glucose to D-glucono-δ-lactone and 
hydrogen peroxide.  Horse radish peroxidase, the 3rd and final enzyme in the enzyme coupled 
reaction, catalyzes the reaction of hydrogen peroxide with amplex red to produce the fluorescent 
product resorufin (43).  Although enzyme coupling increases the opportunity for compound 
interference, it also works to show further selectivity of compounds.     To account for compound 
interference with the enzyme coupled assay, compounds will need to be tested in an assay where 
inorganic phosphate is added to the mixture with compounds and the assay mix in place of the 
ATPase and ATP.   If a compound interferes with the assay in the presence of inorganic 
phosphate, it is likely that that compound is inhibiting one of the enzymes in the assay mix. Final 
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concentrations of DTT were less than 10µM in the reaction mix per the manufacturers 
recommendations to prevent interference with amplex red.  In order to show a compound’s 
selectivity for hsp90, the compounds would also need to tested against other ATPases.  The 
ATPases chosen to test selectivity of these compounds where myosin and kinesin, both motor 
proteins that utilize the energy of ATP hydrolysis to transport cargoes.     
 
 
 
 
4.2  SPECIFIC AIM 
The goal of this work was to characterize selected  hits from the original HCS using an in 
vitro biochemical assay that measures  ATPase activity.  The assays were optimized so that a 
future study could assess compounds for potency, as well as selectivity, using multiple 
recombinant ATPases. 
 
4.3 METHODS 
Isolation of hsc82 yeast, homolog of hsp90 
Recombinant yeast hsp90 (also known as hsc82, hsp90 homolog; chosen for high 
activity) was purified from the yeast strain ECUpep4 (33). This yeast strain contains deletions in 
the chromosomal HSC82 genes and a 2µm URA3 plasmid that encodes and overexpresses 
HSC82 using techniques based on a protocol developed by Dr. David Toft (Mayo Clinic, 
Rochester, MN), modified by Dr. Brodsky lab (44).  Yeast cells were grown in YPD (1% yeast 
extract, 2% peptone, and 2% dextrose) at 26°C to an OD600(optical density at 600nm) of 0.8–1.0 
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(logarithmic phase). Following growth to the logarithmic phase, the cells were collected from the 
growth media by centrifugation for five minutes at 4,700 x g and frozen at -80°C in 50mL 
conical centrifuge tubes for a minimum of 24 hours. Cell pellets were re-suspended in five 
volumes of Buffer 1 (containing 20 mM Tris-HCl, pH 7.5, 4mM EDTA, 1 mM DTT, and 
protease inhibitors (1 mM PMSF, 1 µg/ml leupeptin, 0.5 µg/ml pepstatin A), and lysed by 
bombardment with glass beads (500 µm diameter) using a vortex at its maximum setting six 
times for 30 seconds with 30 second rests on ice. Cells still intact after the lysing step were 
pelleted by centrifugation at 2800 x g for 10 minutes at 4°C and the supernatant was collected.  
The intact cell pellet remaining after the supernatant was decanted was frozen at -80°C to use in 
future hsp90 purifications.  Cell membranes were then removed from the supernatant from the 
previous step by centrifugation at 48,000 x g for 40 minutes at 4°C.  The supernatant was 
collected as cleared lysate and the cell membrane pellet was discarded.  Protein purification was 
completed using the Invitrogen AKTA FPLC system. The cleared lysate was applied to a 5mL 
HiTrap DEAE column from Invitrogen equilibrated in 5 column volumes of buffer 1. The 
column was then washed with 2 column volumes of buffer 1 and with 2 column volumes of 
buffer 1 containing 50 mM KCl. Bound protein was eluted with a continuous KCl gradient from 
0 to 1M KCL in buffer 1.  Fractions were collected and analyzed by sodium sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  The factions that contained a strong 
band at 82kDa were pooled together and desalted on a PD-10 column.  The PD-10 column was 
equilibrated with buffer 2 containing 20 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM EDTA, 1 
mM DTT, 10% glycerol.   2.5mL of sample was added to each PD-10 column.  The sample was 
eluted off the column with 3.5mL of buffer 2 and collected in 1mL fractions.  The dialysate was 
loaded onto a high performance Q-Sepharose column equilibrated in buffer 2, and the column 
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was washed with buffer 2 and then buffer 2 containing 50 mM KCl (flow rate1.0 ml/min) at 4°C. 
Bound protein was eluted with a continuous KCl gradient from 0 M to 1 M KCl. Peak hsp90-
containing fractions, determined by SDS-PAGE, were pooled and dialyzed in a PD-10 column 
against buffer 3 containing 20 mM Tris-HCl, pH 7.5, 50 mM KCl, 0.1 mM EDTA, 1 mM DTT, 
10% glyercol. The final protein concentration was determined using the Peirce 660nm protein 
assay kit (Fisher Scientific, Pittsburgh, PA) with BSA as the standard, and the final purity of 
hsp90 was estimated to be approximately 80% by visual inspection of the SDS-PAGE gels. 
ATPase Activity Assay 
The PiPerTM Phosphate Assay kit was purchased from Fisher Scientific, Pittsburgh, PA.  
Samples containing the phosphate-generating enzyme were diluted to a predetermined 
concentration (determined by enzyme titration) in 1X reaction buffer (either the 0.1M Tris-HCl, 
pH 7.5 buffer provided in the kit or a published reaction buffer for that enzyme).  20µL of the 
diluted enzyme (predetermined for each enzyme, discussed later in the optimization steps) was 
added to each well testing the enzyme in a black 384-well plate.  20µL of reaction buffer, instead 
of diluted enzyme, was added to the negative control wells.  To start the reaction 20µL of a 
working solution (premixed) containing 100 μM Amplex Red reagent, 4 U/mL maltose 
phosphorylase, 0.4 mM maltose, 2 U/mL glucose oxidase, 0.4 U/mL HRP and an experimentally 
predetermined concentration of ATP (different for each enzyme) was added to each well.  The 
plate was centrifuged for 2 minutes at 100 x g.   The plate was then shaken in a microplate 
shaker at a low-medium setting for 1 minute, The plate was read in an M5e microplate reader at 
time 0 in the fluorescence setting with an excitation wavelength of 530nm and an emission 
detection wavelength of 590.  The plate was incubated at 37°C in an incubator and measurements 
were taken every 30 minutes for 4 hours.  
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In order to determine optimal assay conditions, each enzyme was tested in an enzyme 
titration, a substrate titration, and with a known inhibitor.  The length of time required for each 
enzyme to be assayed was determined during the enzyme titration step.   
For the recombinant yeast hsp90 five serial dilutions (7.25µg, 3.63µg, 1.81µg, 906ng, 
and 453ng, of protein per well) were tested in triplicate to determine the optimal amount of 
recombinant yeast hsp90 to be used in the assay.  Based on published results from Availa et al 
2006 and previous experiments, the yeast hsp90 in the PiPer assay working mix was incubated 
for 60 minutes at 37°C before the first read (20).   Hsp90 has a slow turnover rate of ATP 
hydrolysis and it takes at least 60 minutes to start to see activity in the assay. Readings were 
taken at 0, 90, 150, 180, 210, and 240 minutes.   In order to determine the optimal substrate 
concentration six dilutions of ATP (1mM, 500µM, 250µM, 1µM, 500nM, and 250nM) were 
tested in triplicate using the optimal protein amount per well determined in the enzyme titration.  
The final optimization step was to determine the best control inhibitor to use in the assay.  Wells 
containing the predetermined protein amount and substrate concentration were treated with 
20µM 17-AAG and Geldanamycin.  In two separate experiments hsp90 was either pretreated 
with inhibitor and incubated at 37°C for 30 minutes before substrate was added or treated with 
substrate and inhibitor at the same time. 
Kinesin heavy chain motor domain purchased from Cytoskeleton Inc (KR01) was diluted 
in five serial dilutions, (1.4µg, 700ng, 350ng, 175ng, and 0.0875ng) to determine the optimal 
amount of kinesin to add to each well in the PiPer assay.   The plate was incubated at 37°C and 
readings were made at time 0 and subsequently at 20-minute intervals.   The optimal substrate 
concentration was determined by testing the optimal amount of protein determined in the enzyme 
titration with six serial dilutions of ATP, 1mM, 500µM, 250µM, 125µM, 62.5µM, and 31.25µM.   
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Using the optimal kinesin and ATP concentrations determined by the previous experiments, 5’-
adenylylimidodiphosphate (AMP-PNP) was tested in the assay at concentrations of 1mM, 
0.5mM, 0.25mM, and 0.125mM as the control inhibitor.   AMP-PNP is a PAN ATPase inhibitor, used here to inhibit kinesin heavy chain domain because there are no know small-molecule inhibitors of this isoform of kinesin. To determine the optimal amount myosin (rabbit skeletal muscle, Prozyme, MW20)  to use in the PiPer assay five dilutions were tested, 200µg/mL, 100µg/mL, 50µg/mL, 25µg/mL, and 12.5µg/mL.   Using the optimal protein concentration determined in the enzyme titration, the optimal substrate concentration was determined by testing myosin in the PiPer assay with six dilutions of ATP, 1mM, 250µM, 100µM, 50µM, 25µM, and 12.5µM.     
 
 
4.4 RESULTS 
The results of the purification of recombinant yeast hsp90 are shown in the images of the 
SDS-PAGE gels from the purification steps (Figure 13).  The percent purity was estimated from 
these gels by visual estimation. 
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FIGURE 13: SDS-PAGE of Elution Fractions from Hsp90 Purification. 
A) SDS-PAGE of Molecular Weight Standards (Std), Load (L), Flow-through (FT), Wash 1 
(W1), Wash 2 (W2), Wash 3 (W3), Fraction 1 (F1), and Fraction 2 (F2) from DEAE column.  B) 
SDS-PAGE of Molecular Weight Standards (Std), Fractions 1, 2, 3, 4, 5, 6, 7 from first Q-
sepharose column. C) SDS-PAGE of Molecular Weight Standards (Std), Cleared Lysate (CL), 
Lysate (L), Flow-through (FT), Wash (W), and Fractions 10, 11, 12, 13 from second Q-
Sepharose column.  
 
Fraction 12 from the second Q-sepharose column from the hsp90 purification was used in the 
PiPer assay optimization.  The optimal amount of yeast hsp90 to use was determined to be 
6.25ug based on these results and the published results from Availa et al 2006 (45).  The optimal 
time to run the assay was 240 minutes, which was the last time point, based on the signal being 
relatively high and approximately linear at this time point (Figure 14). The amount of substrate 
(ATP) to be used in the assay was determined to be 500µM ATP in a substrate titration (Figure 
15A).   The Km of this protein prep for ATP was estimated to be 188 μM  (Figure 13 B);the 
published Km for yeast hsp90 is 300µM (47). 
 
 
A
 
B C 
 58 
 
 
  
FIGURE 14: Enzyme Titration of Recombinant Yeast Hsp90. 
A) Enzyme titration of hsp90 over time in minutes.  Activity read in relative fluorescence units 
(RFU)   
B) RFU vs protein amount (µg) at 240 minutes. 
Three replicates.  Error bars in standard deviation.  Data representative of three separate 
experiments over three separate days. 
A 
B 
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FIGURE 15: Substrate Titration of Recombinant Yeast Hsp90 
A) Relative fluorescence units over time in minutes for six concentrations of ATP. 
Error bars are in standard deviation, best results of three separate experiments over three 
days, 3 replicates each  
 
A 
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B) Michaelis-Menten kinetics, extrapolated from A) Km = 188 μM  
 
 
In order to determine if hsp90 or a contaminating ATPase produced the ATPase activity 
observed in this protein prep as well as identify a control inhibitor, the protein prep was treated 
with the selective hsp90 inhibitor 17-AAG (31).  The first test wells containing protein were 
treated with inhibitor and the control mix containing ATP was added immediately thereafter 
(Figure 16 A).  The second test wells containing protein were pre-incubated with inhibitor for 30 
minutes and then the working mix was added (Figure 16 B).  In both experiments, no inhibition 
of hsp90 activity by 17-AAG was detected.   
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FIGURE 16: Hsp90 Prep Treated With 17-AAG 
Best results of three separate experiments over three separate days  
A) 6.25µg protein treated with 20µM 17-AAG with 500µM ATP added immediately.  
Control is no protein added with only inhibitor and working mix containing ATP. 
B) 6.25µg protein pre-incubated with 20µM 17-AAG for 30 minutes before 500µM ATP 
added.  Control is no protein added with only inhibitor and working mix containing ATP 
Error bars are in standard deviation.  Three replicates. 
 
 Recombinant kinesin heavy chain motor domain was optimized in the PiPer assay in the 
same order as for hsp90.  The first optimization step was the enzyme titration in which the 
optimal amount of protein was determined to be 700ng per well and the assay run time was 
determined to be 160 minutes because the optimal  protein amount was still linear at this point 
A 
B 
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(Figure 17).   The R2 for concentrations 0.0875µg to 0.7µg per well were 0.98 in a linear 
regression fit.   Conversely, a linear fit for concentrations 0.0875µg to 1.400µg produces a R2 
value of 0.94 using a linear regression curve fit.   This means that the signal starts to saturate 
after 0.7µg. 
 
  
FIGURE 17:  Enzyme Titration Kinesin Heavy Chain Motor Domain 
Best results of three separate experiments over three separate days 
A) Enzyme titration of kinesin heavy chain motor domain over time in minutes Error bars 
are in standard deviation. N = 3 
B) RFU vs protein amount (ug) at 160 minutes. 
A 
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Each test well in the substrate (ATP) titration was loaded with 0.7µg as determined by the 
enzyme titration.  Kinesin was treated with six concentrations of ATP  and 500µM ATP was 
chosen to be the substrate concentration because 500µM ATP produced sufficient  signal  
compared to background(Figure 18A). Based on the Michaelis-Menten kinetics, the Km was 
estimated  to be 53.85µM, which is similar to the published Km of 79± 8 (Figure 18 B) (46).  
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FIGURE 18:  Substrate Titration Kinesin Heavy Chain Motor Domain 
Best results of three separate experiment over three separate days 
A)  Relative fluorescence units over time in minutes for six concentrations of ATP. 
Error bars are in standard deviation, N = 3 
B) Michaelis-Menten kinetics, extrapolated from A) 
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To date there are no known selective small-molecule inhibitors of this kinesin heavy chain motor 
domain so the recommended control inhibitor is AMP-PNP, a non-hydrolyzable analog of ATP.   
Kinesin was not inhibited by AMP-PNP, however it appears to have increased its activity (Figure 
19). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 19:  Kinesin Treated With AMP-PNP 
Controls are kinesin and working mix containing ATP for the positive control and working mix 
and buffer only for the negative control. 
Error bars are in standard deviation. N= 3 
Best results of three separate experiments over three separate days 
 
 The final enzyme that was optimized in the PiPer assay was myosin.  The unique thing 
about myosin compared to kinesin and hsp90 is that with those two enzymes did not require a 
special buffer, whereas myosin required a buffer that is high in salt concentration (Figure 20).  
Kinesin and hsp90 are active in a Tris only buffer, whereas myosin requires a high salt 
concentration for activity.  Using the high salt buffer, the enzyme titration of myosin determined 
that 50µg/mL of protein would give a sufficient signal while minimalizing the amount of enzyme 
required per experiment (Figure 21). 
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FIGURE 20:  Myosin Enzyme Titration Testing Reaction Buffers  
Best results of three separate experiments over three separate days 
A) Myosin in PiPer reaction buffer (100mM Tris-HCl, pH 7.5) 
B) Myosin in high salt buffer (50 mM Tris-HCl, pH7.9, containing 0.23 M KCl, 2.5 mM 
CaCl2).  Error bars represent standard deviation N = 3 
 
 
 
FIGURE 21:  Myosin Enzyme Titration in PiPer Assay. 
Enzyme titration of myosin over time in minutes. 
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Best results of three separate experiments over three different days 
Error bars in standard deviation, N = 3 
 
 
The results from the substrate titration found that 0.25mM ATP is an optimal substrate 
concentration for myosin in the PiPer assay (Figure 22 A).  The Km calculated by the Michaelis 
–Menten curve was 189µM (Figure 20 B); which is consistent with the publish Km of 130 ± 40 
(47).    
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FIGURE 22:  Myosin Substrate Titration 
Best results of three experiments over three separate days 
A) Relative fluorescence units over time in minutes for six concentrations of ATP. 
Error bars are in standard deviation, N = 3 
B) Michaelis-Menten kinetics, extrapolated from A) 
 
 
 
A 
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4.5 DISCUSSION 
 In order to show that a compound is selective for hsp90, the compounds should be tested 
against other ATPases.  To accomplish this myosin and kinesin were chosen.  Before each 
enzyme is tested against the hit compounds they first had to be optimized in the PiPer assay.  The 
goal of the optimization was to identify the minimal amount of protein that produced a strong 
single, the minimal amount of substrate that is required to get a strong signal, and validate that 
the assay could detect  a control inhibitor for each enzyme.  For the hsp90 prep the enzyme and 
substrate titrations produced clear and reproducible results.  However, the Km value that was 
determined by the substrate titration was 188.3µM and the published Km for yeast hsp90 is 
300µM (47).  Also 17-AAG failed to inhibit the ATPase activity of this protein prep. 17-AAG is 
a well-known hsp90 inhibitor and should have inhibited the ATPase activity of this protein prep. 
Given these two results there must be a contaminating ATPase in the protein prep even though 
the SDS-PAGE appears to show relatively pure yeast hsp90 (Figure 13).  In the future, the hsp90 
prep could be further cleaned up with a size exclusion column (49).   
 In the kinesin optimization, the amount of enzyme required in the assay was consistent 
with the published findings (46). However, when kinesin was treated with AMP-PNP there was 
actually an increase in activity compared to the control.   There are a few possibilities as to why 
this happened.  One possibility is that the AMP-PNP is dirty with inorganic phosphate.  If that is 
the case then the AMP-PNP can be cleaned up with a phosphate column.  The other possibility is 
that the AMP-PNP is dirty with ATP.  This can also be cleaned up with a column.  The final 
possibility is that AMP-PNP could be increasing the activity of one of the enzymes in the 
enzyme-coupled assay (50).   
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 The enzyme and substrate titrations of myosin produced reliable and reproducible results.  
The Km calculated by the Michaelis-Menten curve was 189µM, which is consistent with the 
published Km of 130 ± 40 (50).   The next step for myosin is to identify a control inhibitor.  N-
benzyl-p-toluene sulphonamide (BTS) was one suggestion to use as a control inhibitor, but it 
inhibits myosin interactions with f-actin and may not be useful for this study.  As mentioned in 
the introduction in chapter 1, purealin inhibits cytoplasmic dynein and myosin exclusively, so it 
may be a good choice.  Another option is to use AMP-PNP if it can be cleaned up.   
 
5.0 FUTURE DIRECTION 
 The continuation of this study will need to first focus on completing the optimization of 
the three enzymes in the PiPer assay.  This will include either further purifying hsp90 or 
purchasing pure enzyme.  17-AAG should have inhibited the hsp90 prep but did not (45). Once 
the compounds are tested in the PiPer assays and if they are  shown to be selective for hsp90 
ATPase activity they will need to be further validated against GR ligand binding.  Compounds 
that do not inhibit any of the ATPases including hsp90 may be GR antagonists.   In order to test 
the compounds for GR antagonism compounds should be tested in a GR ligand binding assay 
such as a fluorescence polarization (FP) assay (52, 10).   The FP assay will include a GR ligand 
attached to fluorescent tracer compound.  When the labeled GR-ligand binds GR, the FP signal is 
increased and when a test compound interferes with this binding FP will be decreased.  A 
compound’s ability to antagonize GR could  be further explored with a GR-Reporter assay.  The 
reporter assay includes a GR response element that is attached to a gene coding for luciferase 
(52).  When an activated GR bound to GR agonist comes in contact with the response element 
the luciferase will be expressed and luciferase signal will be high.  If a compound is a GR 
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antagonist it will prevent GR activation and there will be little or no luciferase activity.  The 
ultimate conclusion result of these studies is might  be the discovery of  a novel selective hsp90 
inhibitor that does not inhibit kinesin or myosin and does not block GR binding and activation.  
A secondary possibility of a positive result for these  studies might be the discovery of  a novel 
selective inhibitor of the GR.    
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